Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
about
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Agonist OX40 immunotherapy imp ...... GM-CSF-expressing tumor cells.
@en
Agonist OX40 immunotherapy imp ...... GM-CSF-expressing tumor cells.
@nl
type
label
Agonist OX40 immunotherapy imp ...... GM-CSF-expressing tumor cells.
@en
Agonist OX40 immunotherapy imp ...... GM-CSF-expressing tumor cells.
@nl
prefLabel
Agonist OX40 immunotherapy imp ...... GM-CSF-expressing tumor cells.
@en
Agonist OX40 immunotherapy imp ...... GM-CSF-expressing tumor cells.
@nl
P2093
P2860
P356
P1433
P1476
Agonist OX40 immunotherapy imp ...... GM-CSF-expressing tumor cells.
@en
P2093
Hammad Talat
Nusrat Jahan
William T Curry
P2860
P356
10.1093/NEUONC/NOX125
P577
2017-07-07T00:00:00Z